Efficacy and safety of BTX-A in alleviating postoperative pain and reducing capsular contracture after breast augmentation surgery
10.3760/cma.j.cn114657-20241030-00160
- VernacularTitle:A型肉毒毒素用于缓解假体隆乳术后疼痛及降低包膜挛缩的疗效及安全性分析
- Author:
Chong JING
1
;
Xiaopeng WANG
1
;
Zhenggang XIAO
1
Author Information
1. 长沙雅美医疗美容医院美容整形外科，长沙 410000
- Publication Type:Journal Article
- Keywords:
Augmentation mammoplasty;
Type A botulinum toxin;
Pain;
Capsule contracture;
Pectoralis major muscle
- From:
Chinese Journal of Medical Aesthetics and Cosmetology
2025;31(2):167-171
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of type A botulinum toxin (BTX-A) in alleviating pain and reducing capsular contracture after breast augmentation surgery.Methods:This single-center, double-blind, and randomized controlled trial included 212 female patients who underwent breast augmentation surgery at Changsha YaMei Medical Cosmetic Hospital from May 2020 to January 2021. Patients were divided into two groups according to whether BTX-A was injected into the pectoralis major during the augmentation: 106 in the BTX-A group, with an average age of (33.1±3.8) years; and 106 in the control group, with an average age of (33.3±3.5) years. The visual analogue scale (VAS) was used to assess pain on days 1, 3 and 7 post-operation. After two years of follow-up, the postoperative VAS scores, duration of pain, rates of capsular contracture, and incidence of adverse reactions were compared between the two groups.Results:One case was lost to follow-up in each group. On postoperative days 1 and 3, the VAS scores of the BTX-A group were (3.93±1.77) and (5.35±2.04) scores, respectively, lower than those of the control group, which were (5.93±2.17) and (7.34±1.75) scores (both P<0.001). On day 7, the scores were (1.96±1.71) and (2.26±1.90) scores, respectively, with no statistically significant difference ( P=0.225). The pain severity in both groups showed a trend of initial increase followed by a decrease, with a significant difference ( P<0.001). The duration of pain in the BTX-A group was (2.6±1.8) days, shorter than that in the control group (4.9±2.1) days, with a statistically significant difference ( P<0.001). The rate of capsular contracture in the BTX-A group was 0.95% (1/105), compared to 1.90% (2/105) in the control group, with no statistically significant difference ( P=1.000). The incidence of adverse reactions was 11.32% (12/106) in the BTX-A group and 10.38% (11/106) in the control group, with no statistically significant difference ( P=0.825). There were no severe adverse reactions such as respiratory or cardiovascular events or deaths in either group. Conclusion:BTX-A can alleviate pain after breast augmentation surgery with high safety. However, it does not have a significant advantage in preventing capsular contracture.
